Date: 2016-12-04
Type of information: Collaboration agreement
Compound: Myeloma Genome Project
Company: Celgene (USA - NJ) Dana-Farber Cancer Institute (USA - MA) University of Arkansas for Medical Sciences (USA - Ar)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease: myeloma
Details: * On December 4, 2016, Celgene, Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences announced the creation of the Myeloma Genome Project , a collaborative initiative aimed at compiling the largest dataset of high-quality genomic and clinical data to identify distinct molecular disease segments within multiple myeloma to advance diagnosis, prognosis and treatment of multiple myeloma patients. The initiative seeks to develop clinically relevant tests. Details of the project and initial characterization and preliminary analyses of newly diagnosed myeloma patient data were presented by Brian Walker , Ph.D., of the University of Arkansas for Medical Sciences at the 58th American Society of Hematology Annual Meeting in San Diego, Calif.
Current technologies have discovered five major translocation groups within myeloma patients and these mutations have demonstrated varying effects on prognosis. The Myeloma Genome Project is also looking at minor translocation and mutational groups that are often poorly described due to small sample numbers in limited data sets. The group has established a set of 2,161 patients for which whole exome sequencing (WES; n=1,436), whole genome sequencing (WGS; n=708), targeted panel sequencing (n=993) and expression data from RNA-sequencing and gene expression arrays (n=1,497) were available. The data were collected from the Myeloma XI trial ( UK ), Intergroupe Francophone du Myeloma/Dana-Farber Cancer Institute , Myeloma Institute at the University of Arkansas for Medical Sciences and the Multiple Myeloma Research Foundation .
Financial terms:
Latest news:
